Oral Anticoagulation and the Novel Oral Anticoagulants (NOACs):Where Are We at Midterm?

Academic Content

Program Overview

Faculty Presentations

Introduction Deepak L. Bhatt Elaine Hylek

Video Roundtable

Current Activity

Deepak L. Bhatt, MD, MPH
Interventional Cardiovascular Programs
Brigham & Women’s Hospital
Heart & Vascular Center
Harvard Medical School
Boston, Massachusetts

Overview: Anticoag & NOACs AFib Impact AFib in the USA AFib: Age Prevalence AFib: Age & Gender AFib: Age & Strokes Problems with Warfarin Warfarin INR Values & Stroke CHADS2 & AFib - Index Scores CHADS2 & AFib - Patient Scores The REACH Registry: CVD Events CHA2DS2-VASc Stroke Risk The HAS-BLED Risk Score Markov Decision Analysis Novel Oral Anticoagulants NOACS: Risk Prevention Data NOACS: Secondary Efficacy NOACS: Major Bleeding NOACS: Secondary Safety Potentially Preventable Strokes Anticoagulation in VTE Regulatory Approval Status

Return to:

The American Journal of Medicine

« Prev

Next »
Click Figure to Enlarge

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

The American Journal of Medicine

Print This Page

Prevalence of AFib: Age and Gender

The phenomenon of increasing AFib prevalence with age is present in both males and females, although interestingly, as Figure 5 shows, the risk appears to increase a little more with age in males than in females.[3] At the older ages, for example in those >85 years old, the higher prevalence of AFib in men versus women must be adjusted for the fact that a greater proportion of women than men are alive; nevertheless, if one looks at the men versus the women who are alive at that age range, there is still a higher prevalence in males – and this is something that is not commonly appreciated.

Bhatt D. Am J Med 2014; 00.

References

[3]

Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.